Key facts
- Notable investors include Kinled Holding.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Tag Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Tag Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tag Therapeutics
Developer of antisense oligonucleotide therapeutics designed to treat telomere-associated disorders and age-related diseases. The company's platform utilizes a targeted approach to inhibit the DNA damage response specifically at short or damaged telomeres while addressing cellular senescence for idiopathic pulmonary fibrosis, bone marrow failure, and dyskeratosis congenita, enabling patients with telomere biology disorders to benefit from treatments that mitigate disease progression and improve tissue function.
- Sector
- Healthcare
- HQ
- Vienna, Austria
- Founded
- 2025
- Website
- tag-therapeutics.com/
- Ownership
- Privately Held (backing)
Tag Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tag Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tag Therapeutics in its N-PORT filings yet. We sweep new filings monthly.